Publication: Optimising IL-2 for Cancer Immunotherapy
Optimising IL-2 for Cancer Immunotherapy
Date
Date
Date
Citations
Sprent, J., & Boyman, O. (2024). Optimising IL-2 for Cancer Immunotherapy. Immune Network, 24(1), e5. https://doi.org/10.4110/in.2024.24.e5
Abstract
Abstract
Abstract
The key role of T cells in cancer immunotherapy is well established and is highlighted by the remarkable capacity of Ab-mediated checkpoint blockade to overcome T-cell exhaustion and amplify anti-tumor responses. However, total or partial tumor remission following checkpoint blockade is still limited to only a few types of tumors. Hence, concerted attempts are being made to devise new methods for improving tumor immunity. Currently, much attention is being focused on therapy with IL-2. This cytokine is a powerful growth factor for T c
Metrics
Downloads
Views
Additional indexing
Creators (Authors)
- Sprent, Jonathan
- Boyman, Onur
Volume
Volume
Volume
Number
Number
Number
Page range/Item number
Page range/Item number
Page range/Item number
Item Type
Item Type
Item Type
In collections
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Free Access at
Free Access at
Free Access at
Publisher DOI
Metrics
Downloads
Views
Citations
Sprent, J., & Boyman, O. (2024). Optimising IL-2 for Cancer Immunotherapy. Immune Network, 24(1), e5. https://doi.org/10.4110/in.2024.24.e5
